Table 1.
Baseline patient and disease characteristics.
| Patient and disease characteristics, N (%) | All eligible patients (n = 82) |
|---|---|
| Age, median (min, max) | 56.4 (20.7, 88.8) |
| Sex | |
| Female | 15 (18.3) |
| Male | 67 (81.7) |
| Behavioral factors | |
| Smoking w/o regular alcohol | 16 (25.4) |
| Alcohol abuse w/o smoking | 2 (2.4) |
| Smoking and alcohol abuse | 52 (63.4) |
| Neither smoking nor regular alcohol | 6 (7.3) |
| Undetermined | 6 (7.3) |
| Tumor site | |
| Oral cavity | 24 (29.3) |
| Oropharynx | 37 (45.1) |
| Hypopharynx | 14 (17.1) |
| Larynx | 7 (8.5) |
| History of former HNSCC | |
| No | 71 (86.6) |
| Yes | 11 (13.4) |
| T category clinical | |
| T1 | 5 (6.1) |
| T2 | 5 (6.1) |
| T3 | 11 (13.4) |
| T4 | 61 (74.4) |
| Nodal status clinical | |
| N0 | 10 (12.2) |
| N1 | 9 (11.0) |
| N2 | 57 (69.5) |
| N3 | 6 (7.3) |
| Disease stage | |
| SI | 0 (0.0) |
| SII | 3 (3.7) |
| SIII | 5 (6.1) |
| SIV | 74 (90.2) |
| Tumor grade | |
| G1 | 3 (3.6) |
| G2 | 64 (78.1) |
| G3 | 15 (18.3) |
| HPV assessment | |
| HPV-16 DNA positivity | 16 (19.5) |
| p16 protein positivity | 40 (48.8) |
| Radiation dosage (% achieved of planned) | |
| 100% | 73 (89.0) |
| > 70 to < 100% | 9 (11.0) |
| Concomitant chemotherapy | |
| No | 18 (22.0) |
| Yes | 64 (78.0) |